Dr. Pier Paolo Claudio to share knowledge with AACR

The American Association for Cancer Research has invited Dr. Pier Paolo Claudio, a professor of pharmacology and toxicology and CCRI member, to chair, moderate and speak about the functional precision medicine test ChemoID at the symposia on human tumor models during the 2026 AACR Annual Meeting, set for April 17-22 in San Diego. 

Additionally, during the plenary session of the 2025 AACR Special Conference on Functional and Genomic Precision Medicine in Cancer, held in Boston March 11-13, Claudio gave a presentation on the clinical application of cancer stem cells in precision oncology. 

“As the field moves decisively toward patient-centered oncology, it has become increasingly clear that no human tumor model is more biologically relevant than the tumor itself,” Claudio said. “Functional precision medicine approaches such as ChemoID, which, for example, directly test therapeutic responses in a patient’s own live tumor cells, including drug-resistant cancer stem cell populations, represent a critical advance in translating human tumor biology into clinically actionable treatment decisions. I look forward to contributing to a forward-looking discussion on how these models can improve outcomes and reduce ineffective therapy.”